These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37497807)

  • 1. Thyroid function test variability and cardiovascular morbidity in hyperthyroidism.
    Suonsyrjä N; Laihia I; Huhtala H; Jaatinen P; Metso S
    Clin Endocrinol (Oxf); 2023 Oct; 99(4):428-436. PubMed ID: 37497807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
    Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of neonates born to women with Graves' disease: a cohort study.
    Besançon A; Beltrand J; Le Gac I; Luton D; Polak M
    Eur J Endocrinol; 2014 Jun; 170(6):855-62. PubMed ID: 24670885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GENDER INFLUENCES THE CLINICAL PRESENTATION AND LONG-TERM OUTCOME OF GRAVES DISEASE.
    Magri F; Zerbini F; Gaiti M; Capelli V; Ragni A; Rotondi M; Chiovato L
    Endocr Pract; 2016 Nov; 22(11):1336-1342. PubMed ID: 27540885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D; de Nayer P; Bex M;
    Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic Response to Anti-thyroid Drugs in Graves' Hyperthyroidism.
    Abbara A; Clarke SA; Brewster R; Simonnard A; Eng PC; Phylactou M; Papadopoulou D; Izzi-Engbeaya C; Sam AH; Wernig F; Jonauskyte E; Comninos AN; Meeran K; Kelsey TW; Dhillo WS
    Front Endocrinol (Lausanne); 2020; 11():286. PubMed ID: 32477269
    [No Abstract]   [Full Text] [Related]  

  • 7. Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment.
    Žarković M; Wiersinga W; Perros P; Bartalena L; Donati S; Okosieme O; Morris D; Fichter N; Lareida J; Daumerie C; Burlacu MC; Kahaly GJ; Pitz S; Beleslin B; Ćirić J; Ayvaz G; Konuk O; Törüner FB; Salvi M; Covelli D; Curro N; Hegedüs L; Brix T;
    J Endocrinol Invest; 2021 Feb; 44(2):371-378. PubMed ID: 32524368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study.
    Okosieme OE; Taylor PN; Evans C; Thayer D; Chai A; Khan I; Draman MS; Tennant B; Geen J; Sayers A; French R; Lazarus JH; Premawardhana LD; Dayan CM
    Lancet Diabetes Endocrinol; 2019 Apr; 7(4):278-287. PubMed ID: 30827829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Thyroid Hormone Treatment Intensity With Cardiovascular Mortality Among US Veterans.
    Evron JM; Hummel SL; Reyes-Gastelum D; Haymart MR; Banerjee M; Papaleontiou M
    JAMA Netw Open; 2022 May; 5(5):e2211863. PubMed ID: 35552725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Early-Pregnancy Antithyroid Drug Withdrawal in Graves' Disease: A Preliminary Prospective Follow-Up Study.
    Hou X; Guan H; Sun S; Shi Y; Li C; Liu A; Li Y; Gao X; Hou Y; Yang Y; Li Y; Shan Z; Teng W
    Thyroid; 2022 Aug; 32(8):983-989. PubMed ID: 35651276
    [No Abstract]   [Full Text] [Related]  

  • 11. The Mediation Role of Thyrotropin Receptor Antibody in the Relationship Between Age and Severity of Hyperthyroidism in Graves' Disease.
    Suzuki N; Inoue K; Yoshimura R; Kinoshita A; Suzuki A; Fukushita M; Matsumoto M; Yoshihara A; Watanabe N; Noh JY; Katoh R; Sugino K; Ito K
    Thyroid; 2022 Oct; 32(10):1243-1248. PubMed ID: 36074931
    [No Abstract]   [Full Text] [Related]  

  • 12. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
    Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
    J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid-Stimulating Hormone and Thyroid Hormones and Incidence of Diabetes: Prospective Results of the Brazilian Longitudinal Study of Adult Health (ELSA-BRASIL).
    Birck MG; Almeida-Pititto B; Janovsky CCPS; Goulart AC; Santos IS; Teixeira PFDS; Sgarbi JA; Barreto SM; Duncan BB; Schmidt MI; Lotufo PA; Bensenor IM
    Thyroid; 2022 Jun; 32(6):694-704. PubMed ID: 35473396
    [No Abstract]   [Full Text] [Related]  

  • 15. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication.
    Smith J; Brown RS
    Thyroid; 2007 Nov; 17(11):1103-7. PubMed ID: 17822376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent trends in the management of Graves' hyperthyroidism in Japan: opinion survey results, especially on the combination therapy of antithyroid drug and thyroid hormone.
    Mori T; Sugawa H; Kosugi S; Ueda M; Hai N; Matsuda A
    Endocr J; 1997 Aug; 44(4):509-17. PubMed ID: 9447283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications.
    Harvengt J; Boizeau P; Chevenne D; Zenaty D; Paulsen A; Simon D; Guilmin Crepon S; Alberti C; Carel JC; Léger J
    Eur J Endocrinol; 2015 Jun; 172(6):715-23. PubMed ID: 25766047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease.
    Kawakami-Tani T; Fukawa E; Tanaka H; Abe Y; Makino I
    Metabolism; 1997 Oct; 46(10):1184-8. PubMed ID: 9322804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of hyperthyroidism with hypercalcemia in Xindu district and the efficacy of vitamin D3 treatment in these patients: a randomized trial.
    Mei X; Zeng J; Dai WX; Yang HL; Li Y; Tang MW; Qiu P
    Ann Palliat Med; 2021 Sep; 10(9):9640-9649. PubMed ID: 34628889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.